5 - Contents TO DO

6-7 NEWS
TGilead’s Trodelvy approved for breast cancer; NICE recommends long-acting HIV therapy;

8-9 NEWS
First trial of a vaccine against Alzheimer’s; GSK continues to seek a cure for HIV

10-11 CORONAVIRUS NEWS
New COVID-19 variant Omicron prompts global action; Booster pans expanded

12 DARWIN'S MEDICINE
Digital health is both less and more important than you realise

13 POLICY AND PUBLIC HEALTH
Why the new oral pills from Pfizer and Merck and clouding our judgement

14 'TIS THE SEASON TO BE KIND
The more we communicate, the more we inspire others to champion their own acts of kindness

15 PHARMA MARKETERS' BLOG
Is it time to rethink expert engagement?

16-17 COMBATING ANTIMICROBIAL RESISTANCE
To fight the battle against AMR, new, innovative and durable tools are required to diagnose and treat microbial infections

18-19 LIGHTNING SPEED – RAPID DRUG DISCOVERY UNDER THE MICROSCOPE
The role of AI and machine learning in vaccine development

20-21 THE THE NEW NORMAL: GENE THERAPY
Gene therapy is quickly being realised as the new era of medicine, offering a new way of approaching healthcare

22-27 PMEA 2021: A CELEBRATION OF EXCELLENCE IN PATIENT ENGAGEMENT
After hosting a virtual ceremony in 2020, this year’s awards returned to the Royal Lancaster London hotel. We have all the coverage of the night, with photos of all the winners and the full list of winners, highly commended and finalists

30-31 PATIENT-CENTRICITY
Recognising that using technology as a silver bullet approach to individual cases might isolate patients who are unable to access virtual care or need face-to-face support

34-35 PATIENT-REPORTED OUTCOMES – ALL PROS AND NO CONS?
Using patient-reported outcomes to ensure that the patient voice is fully heard in access decisions and tackling the lack of awareness by the regulators and payers of the impact of diseases on patients

36-37 MASTERING RELATIONSHIPS
Strategy experts build trust, up, down and sideways - this series of four articles attempts to capture and communicate the mostly tacit capabilities of a strategy expert in the life sciences sector

42 PEOPLE
Q&A with Simon Wilson

December 2021